Structured Benefit –risk assessment: a review of key publications and initiatives on frameworks and methodologies

Conclusions This article may serve as a starting point for discussions and to reach a mutual consensus for methodology selection in a particular situation. Regulators and pharmaceutical industry should continue to collaborate to develop and take forward BRA methodologies, and by clear communication develop a mutual understanding of the key issues. Copyright © 2015 John Wiley & Sons, Ltd.
Source: Pharmaceutical Statistics - Category: Statistics Authors: Tags: Literature Review Source Type: research